Literature DB >> 11097863

Highly potent nociceptin analog containing the Arg-Lys triple repeat.

K Okada1, T Sujaku, Y Chuman, R Nakashima, T Nose, T Costa, Y Yamada, M Yokoyama, A Nagahisa, Y Shimohigashi.   

Abstract

One of the structural characteristics of a neuropeptide nociceptin is the existence of Arg-Lys (RK) residues at positions 8-9 and 12-13; both RKs have been suggested to bind to the acidic amino acid cluster in the second extracellular loop of the seven transmembrane domain receptor ORL1. With a design strategy of attempting to obtain an analog that binds more strongly to the receptor's acidic cluster, we synthesized a series of nociceptin analogs in which the RK dipeptide unit was placed at positions 6-7, 10-11, or 14-15 adjacent to the parent RKs. Among these nociceptin analogs containing the RK triple repeat, [Arg-Lys(6-7)]- and [Arg-Lys(10-11)]nociceptins exhibited weak activities (6-9 and 60-90% of nociceptin, respectively) both in the receptor binding assay and in the [(35)S]GTPgammaS binding functional assay. In contrast, [Arg-Lys(14-15)]nociceptin was found to be very potent in both assays (3-fold in binding and 17-fold in GTPgammaS functional assay). [Arg-Lys(14-15)]nociceptin was the first peptide analog found to be stronger than the parent nociceptin, and structure-activity studies have suggested that the incorporated Arg-Lys(14-15) interacts with either the receptor acidic amino acid cluster or the receptor aromatic amino acid residues. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097863     DOI: 10.1006/bbrc.2000.3822

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  21 in total

1.  Binding of the novel radioligand [(3)H]UFP-101 to recombinant human and native rat nociceptin/orphanin FQ receptors.

Authors:  Massimo Ibba; Masato Kitayama; John McDonald; Girolamo Calo; Remo Guerrini; Judit Farkas; Geza Toth; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-09-21       Impact factor: 3.000

2.  Anacardic acid-mediated regulation of osteoblast differentiation involves mitigation of inflammasome activation pathways.

Authors:  Meera Venugopal; Jyotsna Nambiar; Bipin G Nair
Journal:  Mol Cell Biochem       Date:  2020-10-22       Impact factor: 3.396

Review 3.  Managing Parkinson's disease: moving ON with NOP.

Authors:  Daniela Mercatelli; Erwan Bezard; Roberto Eleopra; Nurulain T Zaveri; Michele Morari
Journal:  Br J Pharmacol       Date:  2020-01-03       Impact factor: 8.739

Review 4.  Nociceptin/Orphanin FQ Peptide Receptor-Related Ligands as Novel Analgesics.

Authors:  Norikazu Kiguchi; Huiping Ding; Shiroh Kishioka; Mei-Chuan Ko
Journal:  Curr Top Med Chem       Date:  2020       Impact factor: 3.295

5.  Downsizing human, bacterial, and viral proteins to short water-stable alpha helices that maintain biological potency.

Authors:  Rosemary S Harrison; Nicholas E Shepherd; Huy N Hoang; Gloria Ruiz-Gómez; Timothy A Hill; Russell W Driver; Vishal S Desai; Paul R Young; Giovanni Abbenante; David P Fairlie
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-11       Impact factor: 11.205

6.  Activation of the nociceptin/orphanin FQ receptor reduces bronchoconstriction and microvascular leakage in a rabbit model of gastroesophageal reflux.

Authors:  Bruno D'Agostino; Giuseppina Marrocco; Marilisa De Nardo; Girolamo Calò; Remo Guerrini; Luca Gallelli; Charles Advenier; Francesco Rossi
Journal:  Br J Pharmacol       Date:  2005-03       Impact factor: 8.739

7.  Pharmacological characterization of the novel nociceptin/orphanin FQ receptor ligand, ZP120: in vitro and in vivo studies in mice.

Authors:  Anna Rizzi; Daniela Rizzi; Giuliano Marzola; Domenico Regoli; Bjarne Due Larsen; Jorgen Soberg Petersen; Girolamo Calo'
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys.

Authors:  Mei-Chuan Ko; Norah N Naughton
Journal:  J Pain       Date:  2009-02-23       Impact factor: 5.820

9.  Pharmacological profile of the cyclic nociceptin/orphanin FQ analogues c[Cys10,14]N/OFQ(1-14)NH2 and c[Nphe1,Cys10,14]N/OFQ(1-14)NH2.

Authors:  M Kitayama; T A Barnes; G Carra; J McDonald; G Calo; R Guerrini; D J Rowbotham; G Smith; D G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-11-04       Impact factor: 3.000

Review 10.  Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems.

Authors:  Lawrence Toll; Michael R Bruchas; Girolamo Calo'; Brian M Cox; Nurulain T Zaveri
Journal:  Pharmacol Rev       Date:  2016-03-08       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.